PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2024; 16(03): 123-125
DOI: 10.1055/s-0044-1787997
Case Report

Intravenous Ferric Carboxymaltose-Induced Hypophosphatemia in a Patient with Systemic Lupus Erythematosus: Case Report

Sarah Al Qassimi
1   Department of Internal Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
,
Rajaie Namas 
2   Department of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
,
Samer El-Kaissi
3   Department of Endocrinology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
› Institutsangaben Funding and Sponsorship None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Anemia is the most frequently observed hematological alteration in patients with systemic lupus erythematosus. Parenteral iron infusion is a highly effective treatment for the commonly encountered condition of iron deficiency. We report a case of an iron-deficient patient who developed severe symptoms due to hypophosphatemia following the administration of intravenous ferric carboxymaltose. These symptoms included feelings of dizziness and muscle cramping. The necessity to inform doctors and patients about this potential consequence has intensified. With this case report, we hope to raise awareness of the start of screening for this complication in the United Arab Emirates. Patients should also notify the doctor for follow-up if their fatigue worsens or if they develop any new musculoskeletal problems.

Keywords

ferric carboxymaltose - IDA - iron-induced hypophosphatemia - hypophosphatemia - SLE

Authors' Contributions

All authors contributed equally to the writing, editing, and review of the case report.


Compliance with Ethical Principles

None.


Patient Consent

Written informed consent has been obtained from the patient for publication of the submitted article.




Publikationsverlauf

Artikel online veröffentlicht:
06. August 2024

© 2024. The Libyan Biotechnology Research Center. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Glaspy JA, Wolf M, Strauss WE. Intravenous iron-induced hypophosphatemia: an emerging syndrome. Adv Ther 2021; 38 (07) 3531-3549
    CrossrefPubMedSuche in Google Scholar
  • 2 Wolf M, Rubin J, Achebe M. et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA 2020; 323 (05) 432-443
    CrossrefPubMedSuche in Google Scholar
  • 3 Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 2018; 3 (23) e124486
    CrossrefPubMedSuche in Google Scholar
  • 4 Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014; 72 (01) 49-53
    PubMedSuche in Google Scholar
  • 5 Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti Bertrand P. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 2014; 68 (04) 531-533
    CrossrefPubMedSuche in Google Scholar
  • 6 Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep 2017; 2017: bcr2016219160
    CrossrefPubMedSuche in Google Scholar
  • 7 Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis 2012; 60 (04) 655-661
    CrossrefPubMedSuche in Google Scholar